Dr Ian Christopher Lamoureux, MD | |
570 W Brown Rd, Mesa, AZ 85201 | |
(480) 344-2168 | |
(480) 344-2157 |
Full Name | Dr Ian Christopher Lamoureux |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 570 W Brown Rd, Mesa, Arizona |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1588000236 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 58095 (Minnesota) | Secondary |
2084F0202X | Psychiatry & Neurology - Forensic Psychiatry | 55760 (Arizona) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Ian Christopher Lamoureux, MD 2929 E Thomas Rd, Phoenix, AZ 85016-8034 Ph: (602) 470-5000 | Dr Ian Christopher Lamoureux, MD 570 W Brown Rd, Mesa, AZ 85201 Ph: (480) 344-2168 |
News Archive
Although most overweight adults agree that health insurance benefits designed to promote weight loss are a good idea, they don't want to pay extra for them, finds a new study in the American Journal of Preventive Medicine.
Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.
Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, demonstrating that the personalized immunotherapy has a positive impact on the genetic diversity of residual HIV virus, and also results in substantially increased time to viral rebound in HIV patients treated with AGS-004 following antiretroviral therapy (ART) interruption.
Drugs to treat cancer and Alzheimer's disease usually target the active sites of specific protein molecules sustaining the disease. Traditional drug design views proteins as rigid 3-D objects with active sites consisting of surface-accessible "pockets" with a specific, well-defined structure.
VeriChip Corporation ("VeriChip") and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing partnership with RECEPTORS to continue the development of a triage detection system for detection of the H1N1 virus.
› Verified 1 days ago
Amol Rohit Patel, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2028 | |
Dr. Kate Gillpatrick, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2000 | |
Nancy L Vander Veer, PSYD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 602-344-2002 Fax: 480-649-0783 | |
Dr. Yaniv Simon, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2026 Fax: 480-344-0219 | |
Dr. Samuel Hutchinson, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 4135 S Power Rd, Mesa, AZ 85212 Phone: 480-397-2830 | |
Payam M Sadr, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 570 W Brown Rd, Mesa, AZ 85201 Phone: 480-344-2000 Fax: 480-649-0783 | |
Troy Michael Fulton, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3707 E Southern Ave, Mesa, AZ 85206 Phone: 480-509-7738 |